Skip to main content
OpenTrials
Completed

NCT Number: NCT02490345

Gabapentin as Adjunctive Treatment for Postoperative Pain Control

The specific aims of this research study are to use 600 mg gabapentin as an adjunctive treatment for acute postoperative pain control in order to reduce postoperative opiate consumption and improve postoperative pain control.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Eskenazi Health, Indianapolis, Indiana, United States

Loading trial locations.

About this study

After consent has been obtained for the study and the cesarean has been completed, when the participant is in the recovery room, she will take the first pill of the study drug. This will occur approximately 30-60 minutes after the cesarean is completed. The time of first dose will be noted on the data capture form. The following will then occur:

  • Participants will take study capsules (either 600 mg gabapentin or placebo) every 8 hours for the first 48 hours after beginning the study. The nurse on the unit will be sent the study drug in a blinded capsule by the Investigational Pharmacy.
  • Participants will be asked about postoperative pain on a Visual Analog Scale by the care nurses or study personnel before each dose of study drug, before receiving any opioid medication, 2-4 hours after study drugs are consumed, at 24, 36 and 48 hours post surgery, and any other times during routine postoperative clinical care would warrant. Women record pain postoperatively on a similar scale as part of routine clinical care. Prescription pain medication will be given per clinical routine care. Study personnel will note how many pills were sent home.
  • One week (6-9 days) after the cesarean delivery, participants will be contacted by phone or other preferred method and asked about pain score, somnolence scores, dizziness, nausea, depression, any problems they are experiencing, and asked how many pain pills are left in their prescriptions given when they went home. These data will be recorded.

An Edinburgh Depression Scale will also be administered upon consent, at 48 hours, and again at one week after delivery. If the scores meet the specified criteria, the provider will by notified or if the subject has already been discharged from the hospital, she will be given contact information for follow up care.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women at least 18 years of age
  • Singleton gestation
  • Gestational age equal to or greater than 30 weeks
  • Women undergoing a non-emergent (often scheduled) repeat cesarean delivery
  • Spinal anesthesia utilized during cesarean

Exclusion criteria

  • History of opiate abuse
  • Women on opiates during pregnancy
  • Women requiring treatment with magnesium sulfate postpartum
  • Preexisting Fibromyalgia, chronic pain syndrome, or rheumatologic disorder
  • General anesthesia required for cesarean
  • Plans to breastfeed
  • History of major depression or postpartum depression requiring medication
  • Planned classical cesarean section

Treatment and study plan

Gabapentin

Drug

gabapentin usage as adjunctive treatment for pain control

Placebo

Drug

Identical placebo

Primary outcomes

  1. Amount of opioid equivalents consumed

    Time frame: 48 hours after cesarean delivery

Secondary outcomes

  1. Amount of opioid equivalents consumed

    Time frame: one week after cesarean delivery

  2. VAS pain scores

    Time frame: one week after cesarean delivery

  3. Adverse events (somnolence, dizziness, nausea, depression, suicidal ideation, or notable peripheral edema) or drug reactions

    Time frame: one week after cesarean delivery

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Registry information

Official study title

Effect of Gabapentin on Postoperative Pain Control After a Cesarean Section

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jul 3, 2015
Registry last updated
Aug 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.